Significance of ALT/AST ratio for specifying subjects with metabolic syndrome in its silent stage

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 3, Issue 1, 2009, Pages 3-6

  Ohgo, Hideki ^a   Yokoyama, Hirokazu ^a   Hirose, Hiroshi ^a   Kawabe, Hiroshi ^a   Saito, Ikuo ^a   Tomita, Kengo ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

ALT AST; Metabolic syndrome; Non alcoholic fatty liver disease; Visceral fat accumulation; Waist circumference

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; INTRAABDOMINAL FAT; LIPID STORAGE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SEX DIFFERENCE; WAIST CIRCUMFERENCE;

EID: 62749179603     PISSN: 18714021     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dsx.2008.10.001     Document Type: Article

References (26)

1. Vega G.L. Obesity, the metabolic syndrome, and cardiovascular disease. Am Heart J 142 (2001) 1108-1116
2. Matsuzawa Y., Funahashi T., Kihara S., and Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol (2004) 29-33
3. Marchesini G., Brizi M., Moreslli-Labate A.M., Bianchi G., McCulloagh A.J., Forlani V., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 107 (1999) 450-455
4. Bugiansei E., McCullough A.J., and Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42 (2005) 987-1000
5. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., lenzi M., Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 (2003) 917-923
6. Perera S., Lohsoonthorn V., Jiamjarasrangsi W., Lertmaharit S., and Williamns M.A. Association between elevated liver enzymes and metabolic syndrome among Thai adults. Diab. Metab Synd Clin Res Rev 2 (2008) 171-178
7. Schaffler A., Scholmerich J., and Buchler C. Mechanisms of disease adipocytokines and viceral adipose tissue-emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2 (2005) 273-280
8. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., and Cooper G.J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 112 (2003) 91-100
9. Yokoyama H., Hirose H., Ohgo H., and Saito I. Inverse association between serum adiponectin level and transaminase activities in Japanese male workers. J Hepatol 41 (2004) 19-24
10. Targer G., Bertolini L., and Scala L. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol (Oxf.) 61 (2004) 700-703
11. Hui J.M., Hodge A., and Farrell G.C. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 40 (2004) 46-54
12. Alberti K., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
13. Balkau B., and Charles M.A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diab Med 16 (1999) 442-443
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
15. IDF Epidemiology Task Force Consensus Group. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome. ; 2005.
16. Weits T., van der Beek E.J., Wedel M., and Ter Haar Romney B.M. Computed tomography measurement of abdominal fat deposition in relation to anthropometry. Int J Obes 12 (1998) 215-217
17. Home page of the Japanese Ministry of Welfare and Labor [in Japanese].
18. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity. New criteria for 'obesity disease' in Japan. Circ J 66 (2002) 987-992
19. Adibi P., Sadeghi M., Mahsa M., Rozati G., and Mohseni M. Prediction of coronary atherosclerotic disease with liver transaminase level. Liver Int 27 (2007) 895-900
20. Sung K.C., Ryan M.C., and Kim B.S. Relationships between estimates of adiposity, insulin resistance, and nonalcoholic fatty liver disease in a large group of nondiabetic Korean adults. Diab Care 30 (2007) 2113-2118
21. Bedogni G., Bellentain L., Miglioni L., Masutti F., Passalacqua M., Castiglione A., et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6 (2006) 33
22. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000:11;327-32.
23. Katzmarzyk P.T., Janssesn I., Ross R., Church T.S., and Blair S.N. The importance of waist circumference in the definition of metabolic syndrome: prospective analyses of mortality in men. Diab Care 29 (2006) 404-409
24. Nanji A.A., French S.W., and Freeman J.B. Serum alanine aminotransferase to aspartate aminotransferase ratio and degree of fatty liver in morbidly obese patients. Enzyme 36 (1986) 266-269
25. Oh S.Y., Cho Y.K., Kang M.S., Yoo T.W., Park J.H., Kim H.J., et al. The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. Metabolism 55 (2006) 1604-1609
26. Salazar M.R., Carbajal H.A., Curciarello J.O., Aizpura M., Adrover R.E., and Riondet B. Alanine-aminotransferase: an early marker for insulin resistance?. Medicina (B Aires) 67 (2007) 125-130